TORONTO, Nov. 17, 2014 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of PrCelebrex® for the symptomatic relief associated with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. PrTeva-Celecoxib is also indicated for the short-term (≤ 7 days) management of moderate to severe acute pain in adults in conditions such as musculoskeletal and/or soft tissue trauma including sprains, postoperative orthopaedic, and pain following dental extraction.
PrCelebrex® had annual sales of approximately $151 million in Canada, based on IMS Brogan sales data as of September 2014. PrTeva-Celecoxib is available immediately in pharmacies across Canada.
"Arthritis is one of the most prevalent chronic conditions and the economic impact on the Canadian economy in healthcare costs and lost productivity is estimated by The Arthritis Society to be $33 billion each year," said Doug Sommerville, Senior Vice President and General Manager, Teva Canada Limited. "Teva Canada is very pleased to be able to offer our more affordable, bioequivalent version of Celebrex to patients today. New generic launches in Canada over the last three years have saved patients and payers more than $2.3 billion versus the cost of the equivalent brand name drug product – and with today's launch, we are demonstrating our ongoing commitment to playing a critical role in ensuring the sustainability of the healthcare system."
Osteoarthritis, rheumatoid arthritis and ankylosing spondylitis are three of the most common forms of 100+ related conditions all under the overarching umbrella term 'arthritis' that means inflammation ("itis") of the joints ("arthro").i According to The Arthritis Society, more than 4.6 million Canadian adults (one in six Canadians older than 15 years) report having arthritis and by 2036 this number is expected to grow to an estimated 7.5 million Canadian adults.ii
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for almost 50 years, with nearly 200,000iii prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,400 individuals, markets more than 400iv products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs, as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory, oncology, pain, and women's health therapeutic areas, as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.
i Public Health Agency of Canada. Life with Arthritis in Canada: A personal and public health challenge. http://www.phac-aspc.gc.ca/cd-mc/arthritis-arthrite/lwaic-vaaac-10/3-eng.php. Accessed October 28, 2014
ii The Arthritis Society. Arthritis Facts & Figures. http://www.arthritis.ca/facts. Accessed October 28, 2014
iii IMS Compuscript TRx MAT September 2014
iv IMS CD&H MAT September 2014
SOURCE: Teva Canada Limited
For further information: Teva Pharmaceutical Industries Ltd.: Denise Bradley, Vice-President, Head of Global Corporate Reputation, P. 215.591.8974, [email protected]